LP352-201 A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Escalation Study to Investigate the Safety, Tolerability, pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects With Developmental and E

NCT05364021

A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Escalation Study to Investigate the Safety, Tolerability, pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies

Principal Investigator

Sponsor

Longboard Pharmaceuticals

LP352 is being studied to see if it might reduce the number of seizures in patients with DEE. LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders.

This study is currently enrolling.